Abstract
A series of N-aryl derivatives of pyrrole and its related derivatives of fused form (namely; tetrahydroindole and dihydroindenopyrroles) were prepared in fair to good yields. The newly synthesized compounds were confirmed using IR, 1H NMR, Mass spectral and elemental analysis. Tetrahydrobenzo[b] pyrroles Ia-d, 1,4-dihydroindeno[1,2-b]pyrroles IIa,b and pyrroles IIIa-c,e were evaluated for anticancer activity, coinciding with the antioxidant activity; using Di-Phenyl Picryl Hydrazyl (DPPH) tests. The cytotoxicity of the tested compounds (at a concentration of 100 and 200 μg /mL) was performed against HepG-2 and EACC cell lines. Compounds Ib, d and IIa showed promising antioxidant activity beside their anticancer activity. Docking studies were employed to justify the promising anticancer activity of Ib,d and IIa. Protein kinase (PKase)-PDB entry 1FCQ was chosen as target enzyme for this purpose using the MOLSOFT ICM 3.4-8C program. The docking results of the tested compounds went aligned with the respective anticancer assay results.
Keywords: Anticancer, antioxidant, docking, pyrrole, structure-activity-relationship, synthesis.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:A Promising Anti-Cancer and Anti-Oxidant Agents Based on the Pyrrole and Fused Pyrrole: Synthesis, Docking Studies and Biological Evaluation
Volume: 15 Issue: 4
Author(s): Samar Said Fatahala, Emad Ahmed Shalaby, Shaymaa Emam Kassab and Mossad Said Mohamed
Affiliation:
Keywords: Anticancer, antioxidant, docking, pyrrole, structure-activity-relationship, synthesis.
Abstract: A series of N-aryl derivatives of pyrrole and its related derivatives of fused form (namely; tetrahydroindole and dihydroindenopyrroles) were prepared in fair to good yields. The newly synthesized compounds were confirmed using IR, 1H NMR, Mass spectral and elemental analysis. Tetrahydrobenzo[b] pyrroles Ia-d, 1,4-dihydroindeno[1,2-b]pyrroles IIa,b and pyrroles IIIa-c,e were evaluated for anticancer activity, coinciding with the antioxidant activity; using Di-Phenyl Picryl Hydrazyl (DPPH) tests. The cytotoxicity of the tested compounds (at a concentration of 100 and 200 μg /mL) was performed against HepG-2 and EACC cell lines. Compounds Ib, d and IIa showed promising antioxidant activity beside their anticancer activity. Docking studies were employed to justify the promising anticancer activity of Ib,d and IIa. Protein kinase (PKase)-PDB entry 1FCQ was chosen as target enzyme for this purpose using the MOLSOFT ICM 3.4-8C program. The docking results of the tested compounds went aligned with the respective anticancer assay results.
Export Options
About this article
Cite this article as:
Fatahala Said Samar, Shalaby Ahmed Emad, Kassab Emam Shaymaa and Mohamed Said Mossad, A Promising Anti-Cancer and Anti-Oxidant Agents Based on the Pyrrole and Fused Pyrrole: Synthesis, Docking Studies and Biological Evaluation, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (4) . https://dx.doi.org/10.2174/1871520615666150105113946
DOI https://dx.doi.org/10.2174/1871520615666150105113946 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties
Protein & Peptide Letters Apoptosis Induction by Erucylphosphohomocholine via the 18 kDa Mitochondrial Translocator Protein: Implications for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Systemic Approach to the Study of Complex Bone Disorders at the Whole- Genome Level
Current Genomics Multifunctional Anti-Cancer Nano-Platforms are Moving to Clinical Trials
Current Drug Metabolism Target Therapies in Pancreatic Carcinoma
Current Medicinal Chemistry Epidemiology, Clinical Presentation and Treatment of Uveal Melanoma
Clinical Cancer Drugs Somatostatin: A Hormone for the Heart?
Current Vascular Pharmacology Imidazole Scaffold Based Compounds in the Development of Therapeutic Drugs
Current Topics in Medicinal Chemistry MicroRNA Regulation of TRAIL in Renal Carcinoma: Tiny Juggernauts at Work
Current Molecular Pharmacology Principles of Minimally Invasive Parathyroidectomy
Current Medical Imaging Developing of A Novel Clinical Kit for Assaying of Alpha-fetoprotein Based on Luminescent and Magnetic Nanoparticles
Current Nanoscience microRNA-133: Expression, Function and Therapeutic Potential in Muscle Diseases and Cancer
Current Drug Targets Involvement of Targeting and Scaffolding Proteins in the Regulation of the EGFR/Ras/MAPK Pathway in Oncogenesis
Current Signal Transduction Therapy Role of Genetics and Epigenetics in Mucosal, Uveal, and Cutaneous Melanomagenesis
Anti-Cancer Agents in Medicinal Chemistry Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cells
Current Medicinal Chemistry The Phage Display Technique: Advantages and Recent Patents
Recent Patents on DNA & Gene Sequences Anticancer Evaluation and Docking Study of New Bifunctional Phthalazine Derivatives
Current Organic Synthesis Editorial [Low Grade Inflammation as a Common Pathogenetic Denominator in Age-Related Diseases: Novel Drug Targets for Anti-Ageing Strategies and Successful Ageing Achievement. PART I. (Executive Editors: Calogero Caruso Thea Magrone and Emilio Jirilllo)]
Current Pharmaceutical Design ALDH2---The Genetic Polymorphism and Enzymatic Activity Regulation: Their Epidemiologic and Clinical Implications
Current Drug Targets Cordycepin Suppresses Integrin/FAK Signaling and Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry